Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Optimising computerised decision support to transform medication safety and reduce prescriber burden: study protocol for a mixed-methods evaluation of drug-drug interaction alerts.

Baysari MT, Zheng WY, Li L, Westbrook J, Day RO, Hilmer S, Van Dort BA, Hargreaves A, Kennedy P, Monaghan C, Doherty P, Draheim M, Nair L, Samson R.

BMJ Open. 2019 Aug 18;9(8):e026034. doi: 10.1136/bmjopen-2018-026034.

PMID:
31427312
2.

Comparison of the Area-Under-The-Curve for Vancomycin Estimated Using Compartmental and Non-compartmental Methods in Adult Patients with Normal Renal Function.

Shingde RV, Graham GG, Reuter SE, Carland JE, Day RO, Stocker SL.

Ther Drug Monit. 2019 Aug 16. doi: 10.1097/FTD.0000000000000690. [Epub ahead of print]

PMID:
31425492
3.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Milder TY, Stocker SL, Samocha-Bonet D, Day RO, Greenfield JR.

Eur J Clin Pharmacol. 2019 Aug 3. doi: 10.1007/s00228-019-02732-y. [Epub ahead of print] Review.

PMID:
31377891
4.

Education to improve vancomycin use - The perspectives of educators and education recipients.

Van Dort BA, Baysari MT, Carland JE, Stocker SL, Braithwaite HE, Fernon AR, Day RO.

Intern Med J. 2019 Jun 18. doi: 10.1111/imj.14408. [Epub ahead of print]

PMID:
31211885
5.

Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendations.

Tay EM, Preisz P, Day RO.

Emerg Med Australas. 2019 Jun 17. doi: 10.1111/1742-6723.13316. [Epub ahead of print]

PMID:
31207109
6.

Improving adherence to urate-lowering therapy in people living with gout.

Coleshill MJ, Aung E, Nguyen AD, Stocker SL, Baysari MT, Kamel B, Schulz M, McLachlan AJ, Day RO.

Int J Rheum Dis. 2019 Apr;22(4):542-544. doi: 10.1111/1756-185X.13566. No abstract available.

PMID:
30985997
7.

Do user preferences align with human factors assessment scores of drug-drug interaction alerts?

Lowenstein D, Zheng WY, Burke R, Kenny E, Sandhu A, Makeham M, Westbrook J, Day RO, Baysari MT.

Health Informatics J. 2019 Apr 11:1460458219840210. doi: 10.1177/1460458219840210. [Epub ahead of print]

PMID:
30973280
8.

Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance.

Tay E, Sotiriou A, Graham GG, Wilhelm K, Snowden L, Day RO.

Ther Adv Psychopharmacol. 2019 Mar 29;9:2045125319836889. doi: 10.1177/2045125319836889. eCollection 2019. Review.

9.

Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.

Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, Carland JE, Stocker SL, Wicha SG.

Clin Microbiol Infect. 2019 Mar 11. pii: S1198-743X(19)30097-7. doi: 10.1016/j.cmi.2019.02.029. [Epub ahead of print]

PMID:
30872102
10.

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Milder TY, Stocker SL, Abdel Shaheed C, McGrath-Cadell L, Samocha-Bonet D, Greenfield JR, Day RO.

J Clin Med. 2019 Jan 4;8(1). pii: E45. doi: 10.3390/jcm8010045. Review.

11.

Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation.

Meslin SMM, Zheng WY, Day RO, Tay EMY, Baysari MT.

Appl Clin Inform. 2018 Oct;9(4):849-855. doi: 10.1055/s-0038-1676039. Epub 2018 Nov 28.

PMID:
30485879
12.

mHealth App Patient Testing and Review of Educational Materials Designed for Self-Management of Gout Patients: Descriptive Qualitative Studies.

Nguyen AD, Frensham LJ, Wong MX, Meslin SM, Martin P, Lau AY, Baysari MT, Day RO.

JMIR Mhealth Uhealth. 2018 Oct 15;6(10):e182. doi: 10.2196/mhealth.9811.

13.

Reliability, ease of use and usefulness of I-MeDeSA for evaluating drug-drug interaction alerts in an Australian context.

Baysari MT, Lowenstein D, Zheng WY, Day RO.

BMC Med Inform Decis Mak. 2018 Oct 5;18(1):83. doi: 10.1186/s12911-018-0666-y.

14.

Lactic Acidosis, Metformin Use, and Dose-Response Association.

Carland JE, Smith FC, Day RO.

JAMA Intern Med. 2018 Oct 1;178(10):1428-1429. doi: 10.1001/jamainternmed.2018.4448. No abstract available.

PMID:
30285133
15.

Barriers and facilitators of appropriate vancomycin use: prescribing context is key.

Chan JOS, Baysari MT, Carland JE, Sandaradura I, Moran M, Day RO.

Eur J Clin Pharmacol. 2018 Nov;74(11):1523-1529. doi: 10.1007/s00228-018-2525-2. Epub 2018 Jul 28.

PMID:
30056569
16.

Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).

Kumar SS, McManus H, Radovich T, Greenfield JR, Viardot A, Williams KM, Cronin P, Day RO.

Eur J Clin Pharmacol. 2018 Oct;74(10):1327-1332. doi: 10.1007/s00228-018-2506-5. Epub 2018 Jun 24.

PMID:
29938343
17.

Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Graham GG, Stocker SL, Kannangara DRW, Day RO.

Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2. Review.

PMID:
29931553
18.

Patients' use of mobile health applications: what general practitioners think.

Nguyen AD, Frensham LJ, Baysari MT, Carland JE, Day RO.

Fam Pract. 2019 Mar 20;36(2):214-218. doi: 10.1093/fampra/cmy052.

PMID:
29873708
19.

Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study.

Counsell AB, Nguyen AD, Baysari MT, Kannangara DRW, McLachlan AJ, Day RO.

BMC Fam Pract. 2018 May 9;19(1):54. doi: 10.1186/s12875-018-0744-3.

20.

Predicting 7-day, 30-day and 60-day all-cause unplanned readmission: a case study of a Sydney hospital.

Maali Y, Perez-Concha O, Coiera E, Roffe D, Day RO, Gallego B.

BMC Med Inform Decis Mak. 2018 Jan 4;18(1):1. doi: 10.1186/s12911-017-0580-8.

21.

Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis.

Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT.

Eur J Clin Pharmacol. 2018 Jan;74(1):15-27. doi: 10.1007/s00228-017-2357-5. Epub 2017 Oct 23. Review.

PMID:
29058038
22.

Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.

Day RO, Frensham LJ, Nguyen AD, Baysari MT, Aung E, Lau AYS, Zwar N, Reath J, Laba T, Li L, McLachlan A, Runciman WB, Buchbinder R, Clay-Williams R, Coiera E, Braithwaite J, McNeil HP, Hunter DJ, Pile KD, Portek I, WIlliams KM, Westbrook JI.

BMJ Open. 2017 Oct 16;7(10):e017281. doi: 10.1136/bmjopen-2017-017281.

23.

Use of colchicine in pregnancy: a systematic review and meta-analysis.

Indraratna PL, Virk S, Gurram D, Day RO.

Rheumatology (Oxford). 2018 Feb 1;57(2):382-387. doi: 10.1093/rheumatology/kex353. Review.

PMID:
29029311
24.

STANDING Collaboration: a study protocol for developing clinical standards.

Wiles LK, Hibbert PD, Stephens JH, Coiera E, Westbrook J, Braithwaite J, Day RO, Hillman KM, Runciman WB.

BMJ Open. 2017 Oct 11;7(10):e014048. doi: 10.1136/bmjopen-2016-014048.

25.

Redesign of computerized decision support to improve antimicrobial prescribing. A controlled before-and-after study.

Baysari MT, Del Gigante J, Moran M, Sandaradura I, Li L, Richardson KL, Sandhu A, Lehnbom EC, Westbrook JI, Day RO.

Appl Clin Inform. 2017 Sep 13;8(3):949-963. doi: 10.4338/ACI2017040069.

26.

Life-threatening drug interactions: what the physician needs to know.

Day RO, Snowden L, McLachlan AJ.

Intern Med J. 2017 May;47(5):501-512. doi: 10.1111/imj.13404. Review.

PMID:
28503886
27.

Introduction to the Special Section: Phase I Clinical Trials.

Day RO.

Ther Innov Regul Sci. 2017 May;51(3):274-275. doi: 10.1177/2168479017706513. No abstract available.

PMID:
30231701
28.

A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function.

Duong JK, Kroonen MYAM, Kumar SS, Heerspink HL, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Eur J Clin Pharmacol. 2017 Aug;73(8):981-990. doi: 10.1007/s00228-017-2251-1. Epub 2017 Apr 28.

PMID:
28451709
29.

Individualising the dose of allopurinol in patients with gout.

Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.

Br J Clin Pharmacol. 2017 Sep;83(9):2015-2026. doi: 10.1111/bcp.13307. Epub 2017 May 28.

30.

Trial of Pregabalin for Acute and Chronic Sciatica.

Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, Harris I, Day RO, Billot L, Pik J, Jan S, Lin CC.

N Engl J Med. 2017 Mar 23;376(12):1111-1120. doi: 10.1056/NEJMoa1614292.

31.

Automation bias in electronic prescribing.

Lyell D, Magrabi F, Raban MZ, Pont LG, Baysari MT, Day RO, Coiera E.

BMC Med Inform Decis Mak. 2017 Mar 16;17(1):28. doi: 10.1186/s12911-017-0425-5.

32.

Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.

Machado GC, Maher CG, Ferreira PH, Day RO, Pinheiro MB, Ferreira ML.

Ann Rheum Dis. 2017 Jul;76(7):1269-1278. doi: 10.1136/annrheumdis-2016-210597. Epub 2017 Feb 2. Review.

PMID:
28153830
33.

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Review.

PMID:
27927043
34.

CareTrack: Toward Appropriate Care for Low Back Pain.

Ramanathan SA, Hibbert PD, Maher CG, Day RO, Hindmarsh DM, Hooper TD, Hannaford NA, Runciman WB.

Spine (Phila Pa 1976). 2017 Jul 1;42(13):E802-E809. doi: 10.1097/BRS.0000000000001972.

PMID:
27831965
35.

Xanthine oxidoreductase and its inhibitors: relevance for gout.

Day RO, Kamel B, Kannangara DR, Williams KM, Graham GG.

Clin Sci (Lond). 2016 Dec 1;130(23):2167-2180. Review.

PMID:
27798228
36.

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Kamel B, Graham GG, Williams KM, Pile KD, Day RO.

Clin Pharmacokinet. 2017 May;56(5):459-475. doi: 10.1007/s40262-016-0466-4. Review.

PMID:
27753003
37.

Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration.

Smith FC, Kumar SS, Furlong TJ, Gangaram SV, Greenfield JR, Stocker SL, Graham GG, Williams KM, Day RO.

Am J Kidney Dis. 2016 Dec;68(6):990-992. doi: 10.1053/j.ajkd.2016.08.017. Epub 2016 Oct 15. No abstract available.

PMID:
27751611
38.

Could metformin be used in patients with advanced chronic kidney disease?

Kumar SS, Graham GG, Smith FC, Furlong TJ, Greenfield JR, Stocker SS, Carland JE, Day RO.

Diabetes Obes Metab. 2017 Feb;19(2):302-303. doi: 10.1111/dom.12806. Epub 2016 Nov 9. No abstract available.

PMID:
27735109
39.

The economic burden of guideline-recommended first line care for acute low back pain.

Lin CC, Li Q, Williams CM, Maher CG, Day RO, Hancock MJ, Latimer J, Mclachlan AJ, Jan S.

Eur Spine J. 2018 Jan;27(1):109-116. doi: 10.1007/s00586-016-4781-0. Epub 2016 Sep 21.

PMID:
27652679
40.

Severe GHB withdrawal delirium managed with dexmedetomidine.

Tay EM, Graham RI, Day RO.

Med J Aust. 2016 Sep 19;205(6):251-2. No abstract available.

PMID:
27627929
41.

The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia.

Walter SR, Day RO, Gallego B, Westbrook JI.

Br J Clin Pharmacol. 2017 Feb;83(2):416-426. doi: 10.1111/bcp.13124. Epub 2016 Sep 29.

42.

Mobile applications to enhance self-management of gout.

Nguyen AD, Baysari MT, Kannangara DR, Tariq A, Lau AY, Westbrook JI, Day RO.

Int J Med Inform. 2016 Oct;94:67-74. doi: 10.1016/j.ijmedinf.2016.06.021. Epub 2016 Jun 30.

PMID:
27573313
43.

Trends in metformin utilisation and dose appropriateness in Australia.

Moon J, Kumar SS, Graham GG, Baysari MT, Williams KM, Chen W, Viardot A, Greenfield JR, Day RO.

Eur J Clin Pharmacol. 2016 Dec;72(12):1489-1496. Epub 2016 Aug 27.

PMID:
27568311
44.

OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol.

Lin CW, McLachlan AJ, Latimer J, Day RO, Billot L, Koes BW, Maher CG.

BMJ Open. 2016 Aug 24;6(8):e011278. doi: 10.1136/bmjopen-2016-011278.

45.

Evaluation of hospital-wide computerised decision support in an intensive care unit: an observational study.

Santucci W, Day RO, Baysari MT.

Anaesth Intensive Care. 2016 Jul;44(4):507-12.

46.

Where to find information about drugs.

Day RO, Snowden L.

Aust Prescr. 2016 Jun;39(3):88-95. doi: 10.18773/austprescr.2016.023. Epub 2016 Jun 1. Review.

47.

The effectiveness of information technology to improve antimicrobial prescribing in hospitals: A systematic review and meta-analysis.

Baysari MT, Lehnbom EC, Li L, Hargreaves A, Day RO, Westbrook JI.

Int J Med Inform. 2016 Aug;92:15-34. doi: 10.1016/j.ijmedinf.2016.04.008. Epub 2016 Apr 30. Review.

PMID:
27318068
48.

Alert override as a habitual behavior - a new perspective on a persistent problem.

Baysari MT, Tariq A, Day RO, Westbrook JI.

J Am Med Inform Assoc. 2017 Mar 1;24(2):409-412. doi: 10.1093/jamia/ocw072.

PMID:
27274015
49.

A time and motion study of junior doctor work patterns on the weekend: a potential contributor to the weekend effect?

Richardson LC, Lehnbom EC, Baysari MT, Walter SR, Day RO, Westbrook JI.

Intern Med J. 2016 Jul;46(7):819-25. doi: 10.1111/imj.13120.

PMID:
27094756
50.

Exploring sub-optimal use of an electronic risk assessment tool for venous thromboembolism.

Baysari MT, Jackson N, Ramasamy S, Santiago P, Xiong J, Westbrook J, Omari A, Day RO.

Appl Ergon. 2016 Jul;55:63-69. doi: 10.1016/j.apergo.2016.01.003. Epub 2016 Jan 29.

PMID:
26995037

Supplemental Content

Support Center